What is HC Wainwright’s Forecast for MIRM FY2030 Earnings?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at HC Wainwright issued their FY2030 EPS estimates for Mirum Pharmaceuticals in a research note issued on Monday, January 26th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of $6.16 per share for the year. HC Wainwright currently has a “Buy” rating and a $130.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share.

A number of other equities analysts have also commented on the company. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, January 12th. Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Finally, JMP Securities set a $95.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.92.

Mirum Pharmaceuticals Trading Up 1.6%

NASDAQ MIRM opened at $100.85 on Tuesday. The firm has a market capitalization of $5.18 billion, a PE ratio of -117.27 and a beta of 0.48. The business’s 50-day moving average price is $78.97 and its two-hundred day moving average price is $71.75. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals has a 12 month low of $36.88 and a 12 month high of $101.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.Mirum Pharmaceuticals’s revenue for the quarter was up 47.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) EPS.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, Director Patrick J. Heron purchased 131,425 shares of Mirum Pharmaceuticals stock in a transaction on Friday, January 23rd. The stock was acquired at an average cost of $68.48 per share, for a total transaction of $8,999,984.00. Following the completion of the acquisition, the director owned 459,010 shares of the company’s stock, valued at $31,433,004.80. This trade represents a 40.12% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Joanne Quan sold 6,911 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $90.27, for a total transaction of $623,855.97. Following the transaction, the insider owned 11,305 shares in the company, valued at $1,020,502.35. This represents a 37.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 32,429 shares of company stock valued at $3,039,396 over the last 90 days. Insiders own 22.87% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in MIRM. MCF Advisors LLC boosted its holdings in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals during the third quarter valued at about $33,000. Quarry LP purchased a new position in Mirum Pharmaceuticals during the third quarter worth about $41,000. CWM LLC increased its stake in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after buying an additional 161 shares during the last quarter. Finally, Comerica Bank increased its stake in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the last quarter.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron bought 131,425 shares at $68.48 (~$9.0M), increasing his stake ~40% — a strong insider vote of confidence that typically supports share demand. Heron Form 4
• Positive Sentiment: HC Wainwright reiterated a Buy and raised its price target (reported lift to $130) while publishing bullish long‑term EPS projections (notably aggressive FY2030 and FY2029 estimates), which supports higher valuation expectations and likely attracted momentum buyers. Analyst Upgrade / 52‑Week High
• Positive Sentiment: Mirum completed its acquisition of Bluejay Therapeutics, expanding its rare‑disease pipeline and potential future revenue streams — a strategic corporate development investors view as accretive. Acquisition Announcement
• Neutral Sentiment: HC Wainwright adjusted near‑term EPS forecasts (cut FY2027 and trimmed FY2028 modestly) while raising longer‑range estimates — mixed guidance that tempers but does not negate the bullish long‑term thesis. HC Wainwright Estimates
• Negative Sentiment: Several senior executives sold stock on Jan 26 at about $96.19: CEO Christopher Peetz (6,831 shares, ≈$657K), COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares), and SVP Jolanda Howe (842 shares). Multiple insider sales on the same day can raise near‑term investor caution about insider liquidity needs despite the large director buy. CEO Form 4 COO Form 4 CFO Form 4 SVP Form 4

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.